Vaccine and immunotherapy for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new type of vaccine (called ONVAX-01) combined with an immunotherapy drug and chemotherapy for advanced pancreatic cancer. The goal is to see if this combination can help your immune system fight the cancer more effectively than the usual treatments alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced pancreatic cancer that has spread and has a KRAS gene mutation.
- Your cancer has gotten worse after at least one prior treatment.
- You are in generally good health and able to care for yourself.
- You have not been treated with certain immunotherapy drugs before.
- Your organ function (like liver, kidney, blood counts) is adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy (called Lm-LLO-TT) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and effective.
This trial tests giving a combination of an oncolytic virus, immunotherapy (PD-1 inhibitor), and chemotherapy before surgery to shrink pancreatic tumors and make them easier to remove. The goal is to improve outcomes for people with borderline resectable or locally advanced pancreatic cancer.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests a new treatment that combines a cancer-killing virus with an immunotherapy drug (a PD-1 inhibitor) for advanced pancreatic cancer. It aims to see if this combination can help shrink tumors and improve outcomes for patients who have already tried chemotherapy.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
This trial tests a new combination of an immunotherapy drug (QL1706) and two chemotherapy medicines (AG) as the first treatment for advanced pancreatic cancer. The goal is to see if the combination can shrink tumors and help patients live longer.
Hear when a new Advanced Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.